Heterogeneity of treatment response in bronchiectasis clinical trials.

Oriol SibilaElena LasernaAmelia ShoemarkLidia PereaDiana BiltonMegan L CrichtonAnthony De SoyzaWim G BoersmaJosje AltenburgJames D Chalmers

Published in: The European respiratory journal (2021)

Improvements in lung function, symptoms and exacerbation frequency are dissociated in bronchiectasis. FEV1 is poorly responsive and poorly correlated with other key outcome measures. Clinical parameters are poorly predictive of treatment response suggesting the need to develop biomarkers to identify responders.

Keyphrases

lung function
cystic fibrosis
chronic obstructive pulmonary disease
clinical trial
air pollution
single cell
cancer therapy
sleep quality
drug delivery
intensive care unit